Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-label Dose Escalation Study of Single Oral Daily Doses of BIBW 2992 for Three Days After Administration of Docetaxel, in Patients With Advanced Solid Tumors

NCT02171676 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02171676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02171676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-label Dose Escalation Study of Single Oral Daily Doses of BIBW 2992 for Three Days After Administration of Docetaxel, in Patients With Advanced Solid Tumors
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2005
Completion date
Not reported
Enrollment
40 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms